mdgl: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	247,028	10,381
Net increase in cash, cash equivalents, and restricted cash	195,675	86,174
Cash and cash equivalents at beginning of period	105,019	-
Cash and cash equivalents at end of period	300,694	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by financing activities	247,028	10,381
Net increase in cash, cash equivalents, and restricted cash	195,675	86,174
Cash and cash equivalents at beginning of period	105,019	-
Cash and cash equivalents at end of period	300,694	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

MADRIGAL PHARMACEUTICALS, INC. (MDGL)